尤瑞克林治疗急性大面积脑梗死疗效分析  

Clinical Analysis of Urinary Kallidinogenase Treatment on Acute Massive Cerebral Infarction

作　　者：陈敏[1] 黄金棋[1] 翁隽挺[1] 方德祥[1] 黄汉东[1] 

机构地区：[1]莆田学院附属医院神经内科,福建莆田351100

出　　处：《神经损伤与功能重建》2011年第6期410-412,共3页Neural Injury and Functional Reconstruction

摘　　要：目的:观察尤瑞克林治疗急性大面积脑梗死的疗效。方法:急性大面积脑梗死患者80例,随机分为尤瑞克林组40例,常规组40例;2组均给予神经内科常规治疗,尤瑞克林组在此基础上,给予尤瑞克林治疗;于治疗后3周进行死亡率统计;于治疗前及治疗后第1、2、3周行头颅CT扫描并计算脑梗死病灶体积;于治疗前及治疗后第3周分类统计NIHSS评分。结果:治疗3周后,尤瑞克林组死亡率低于常规组(P<0.05),治疗后第1、2、3周脑梗死病灶体积均小于常规组(P<0.05),治疗后第3周NIHSS的意识、颅神经、运动神经评分低于常规组(P<0.05),NIHSS的感觉神经及语言评分2组间差异无统计学意义。结论:尤瑞克林治疗可明显降低急性大面积脑梗死患者的死亡率,减小脑梗死病灶体积,对意识、颅神经及运动神经功能障碍的修复有较好的亲合力。Objective： To observe the efficacy of urinary kallidinogenase treatment on acute massive cerebral infarction. Methods： Eighty patients with acute massive cerebral infarction were enrolled and randomly divided into treatment group （n=40） and control group （n：40）. All the cases were treated with conventional neurologic therapy and cases in the treatment group were ad- ditionally treated with urinary kallidinogenase. The mortality rates and the NIHSS scores in dif- ferent domains were compared between the two groups at 3 weeks after treatment. The volumes of infarction were compared between the two groups at 1, 2 and 3 weeks after the treatment. Re- sults： The mortality rate of the treatment group was significantly lower and the volumes of in- farction were smaller than those of the control group （P%0.05）. The NIHSS scores of aware- ness, the cranial nerves and motor function of the cases in the treatment group were lower than those in the control group （P^0.05） whereas the scores of the sensory nerves and the language showed no differences between the two groups. Conclusion： The application of urinary kallidino- genase to patients with acute massive cerebral infarction helps to decrease the mortality rate and the volume of infarction, and enhances the recovery of neurologic deficits in awareness, the crani- al nerves and motor function.

关 键 词：尤瑞克林 急性大面积脑梗死 美国国立卫生院脑卒中量表 

分 类 号：R741[医药卫生—神经病学与精神病学] R741.05[医药卫生—临床医学]